162 related articles for article (PubMed ID: 21533858)
21. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Naruse K; Yamada Y; Nakamura K; Aoki S; Taki T; Zennami K; Katsuda R; Watanabe M; Nishikawa G; Itoh Y; Mitsui K; Hibi H; Honda N
Oncol Rep; 2010 Jun; 23(6):1577-83. PubMed ID: 20428812
[TBL] [Abstract][Full Text] [Related]
22. Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer.
Agrawal U; Mishra AK; Salgia P; Verma S; Mohanty NK; Saxena S
Pathol Oncol Res; 2011 Mar; 17(1):91-101. PubMed ID: 20571940
[TBL] [Abstract][Full Text] [Related]
23. Expression of aquaporin 1 in bladder uroepithelial cell carcinoma and its relevance to recurrence.
Liu J; Zhang WY; Ding DG
Asian Pac J Cancer Prev; 2015; 16(9):3973-6. PubMed ID: 25987071
[TBL] [Abstract][Full Text] [Related]
24. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
25. Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers.
Bruyere F; Namdarian B; Corcoran NM; Pedersen J; Ockrim J; Voelzke BB; Mete U; Costello AJ; Hovens CM
Urol Oncol; 2010; 28(6):591-6. PubMed ID: 19162513
[TBL] [Abstract][Full Text] [Related]
26. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors.
Oosterhuis JW; Schapers RF; Janssen-Heijnen ML; Smeets AW; Pauwels RP
Cancer; 2000 Jun; 88(11):2598-605. PubMed ID: 10861439
[TBL] [Abstract][Full Text] [Related]
27. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Sun YW; Xuan Q; Shu QA; Wu SS; Chen H; Xiao J; Xiang P; Zhu YP; Wang FL; Zhao ST
Genet Mol Res; 2013 Apr; 12(2):1045-53. PubMed ID: 23613251
[TBL] [Abstract][Full Text] [Related]
28. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
30. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
[TBL] [Abstract][Full Text] [Related]
31. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
[TBL] [Abstract][Full Text] [Related]
32. Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non-muscle-invasive bladder cancer. A step forward or back?
Pellucchi F; Freschi M; Moschini M; Rocchini L; Maccagnano C; Nazareno S; Bergamaschi F; Montorsi F; Colombo R
BJU Int; 2015 Feb; 115(2):267-73. PubMed ID: 25756136
[TBL] [Abstract][Full Text] [Related]
33. Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues.
Jiang YQ; Zhong TF; Dang YW; Zou LS; Yang L; Yang X; Chen G
Asian Pac J Cancer Prev; 2014; 15(21):9137-42. PubMed ID: 25422191
[TBL] [Abstract][Full Text] [Related]
34. [Clinical evaluation of grade 3 superficial bladder cancer].
Shinohara M; Inoue Y; Itakura H; Munakata A; Kinoshita K
Nihon Hinyokika Gakkai Zasshi; 1996 Jun; 87(6):892-9. PubMed ID: 8753007
[TBL] [Abstract][Full Text] [Related]
35. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Chang CC; Shieh GS; Wu P; Lin CC; Shiau AL; Wu CL
Cancer Res; 2008 Aug; 68(15):6281-91. PubMed ID: 18676852
[TBL] [Abstract][Full Text] [Related]
36. Expression of Bmi-1 is a prognostic marker in bladder cancer.
Qin ZK; Yang JA; Ye YL; Zhang X; Xu LH; Zhou FJ; Han H; Liu ZW; Song LB; Zeng MS
BMC Cancer; 2009 Feb; 9():61. PubMed ID: 19228380
[TBL] [Abstract][Full Text] [Related]
37. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
38. D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy.
Okajima E; Tomizawa M; Shimada K; Negishi T; Nishiyama N; Kitamura H
Urol Oncol; 2020 Oct; 38(10):797.e7-797.e13. PubMed ID: 32576528
[TBL] [Abstract][Full Text] [Related]
39. A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer.
Chen JX; Deng N; Chen X; Chen LW; Qiu SP; Li XF; Li JP
Asian Pac J Cancer Prev; 2012; 13(5):2229-34. PubMed ID: 22901199
[TBL] [Abstract][Full Text] [Related]
40. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
